Back

The GLP-1 receptor agonist Semaglutide preserves cardiac function, reduces inflammation-driven cardiotoxicity with cardio-renal benefits in non-diabetic models exposed to anthracyclines and HER2 block

9 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: CKM syndrome in practice: risk, mechanisms, and therapy Cardio-Oncology Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

5 More presentations in this session

Presentation thumbnail
Drug therapy in patients with heart failure with reduced left ventricular ejection fraction and chronic kidney disease stages 4-5: a medical challenge.
Doctor M. Anguita Sanchez (Cordoba, ES)
Abstract Slides
Presentation thumbnail
Stage 2 cardiovascular-kidney-metabolic syndrome and the risk of heart failure
Doctor K. Teramoto (Osaka, JP)
Abstract Slides
Presentation thumbnail
Non conventional risc factors for coronary heart disease in end stage renal disease patients.
Doctor E. Shkembi (Vlora, AL)
Abstract Slides
Presentation thumbnail
Association of albuminuria with left atrial remodeling and left ventricular diastolic function in non-dialysis chronic kidney disease patients
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides
Presentation thumbnail
Finerenone and all-cause hospitalization in cardiovascular-kidney-metabolic disease
Doctor J. Ostrominski (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
CKM syndrome in practice: risk, mechanisms, and therapy

The Event

Event poster

Heart Failure 2026

9 May 2026 13:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources